| An Investigational Immuno-Therapy Safety and Efficacy Study of Multiple Administration Regimens for Nivolumab Plus Ipilimumab in Subjects With Renal Cell Carcinoma (NCT03029780) | Bristol-Myers Squibb | 2017-02-16 |
| A Study to Evaluate the Safety of Nivolumab and Ipilimumab in Subjects With Previously Untreated Advanced or Metastatic Renal Cell Cancer (NCT02982954) | Bristol-Myers Squibb | 2017-01-16 |
| A Study of Atezolizumab as Adjuvant Therapy in Participants With Renal Cell Carcinoma (RCC) at High Risk of Developing Metastasis Following Nephrectomy (NCT03024996) | Hoffmann-La Roche | 2017-01-03 |
| Moesin Expression in Clear Cell Renal Cell Carcinoma (NCT06055660) | Sohag University | 2017-01-01 |
| A Study of BBI503 in Adult Patients With Advanced Urologic Malignancies (NCT02232646) | Sumitomo Pharma America, Inc. | 2017-01-01 |
| Neoadjuvant MEDI 4736 +/- Tremelimumab in Locally Advanced Renal Cell Carcinoma (NCT02762006) | Moshe Ornstein | 2016-12-20 |
| A Dose Escalation and Cohort Expansion Study of NKTR-214 in Combination With Nivolumab and Other Anti-Cancer Therapies in Patients With Select Advanced Solid Tumors (NCT02983045) | Nektar Therapeutics | 2016-12-19 |
| A Study to Observe the Treatment Patterns and Outcomes of Patients in Japan With Kidney Cancer That is Unable to be Removed by Surgery or That Has Spread (NCT03161145) | Bristol-Myers Squibb | 2016-12-09 |
| HKT288 in Solid Tumors, Including Epithelial Ovarian Cancer and Renal Cell Carcinoma (NCT02947152) | Novartis Pharmaceuticals | 2016-12-01 |
| Isoquercetin as an Adjunct Therapy in Patients With Kidney Cancer Receiving First-line Sunitinib: a Phase I/II Trial (NCT02446795) | Consorzio Oncotech | 2016-11-01 |
| Real-Life Effectiveness and Safety in Participants With Advanced/Metastatic Renal Cell Carcinoma Starting 1st Line Nivolumab and Ipilimumab Combination Therapy or Nivolumab Monotherapy After Prior Therapy (NCT02940639) | Bristol-Myers Squibb | 2016-10-27 |
| Stereotactic Radiotherapy and Anti-PD1 Antibody (Pembrolizumab) for Oligometastatic Renal Tumours (NCT02855203) | Peter MacCallum Cancer Centre, Australia | 2016-10-20 |
| Clinical Outcome Of Advanced Renal Cell Carcinoma In Taiwan (NCT02776644) | Pfizer | 2016-10-15 |
| Lenvatinib/Everolimus or Lenvatinib/Pembrolizumab Versus Sunitinib Alone as Treatment of Advanced Renal Cell Carcinoma (NCT02811861) | Eisai Inc. | 2016-10-13 |
| Study of Pembrolizumab (MK-3475) Monotherapy in Locally Advanced/Metastatic Renal Cell Carcinoma (MK-3475-427/KEYNOTE-427) (NCT02853344) | Merck Sharp & Dohme LLC | 2016-09-30 |
| Study to Evaluate the Efficacy and Safety of Pembrolizumab (MK-3475) in Combination With Axitinib Versus Sunitinib Monotherapy in Participants With Renal Cell Carcinoma (MK-3475-426/KEYNOTE-426) (NCT02853331) | Merck Sharp & Dohme LLC | 2016-09-16 |
| DC1s-CTL Cellular Therapy for Renal Cell Carcinoma (NCT02787915) | Xuzhou Medical University | 2016-09-01 |
| Prospective Versus Retrospective Complications in Radical Cystectomy and Nephrectomy (NCT03052504) | Jørgen Bjerggaard Jensen | 2016-09-01 |
| Study of HBI-8000 With Nivolumab in Melanoma, Renal Cell Carcinoma and Non-Small Cell Lung Cancer (NCT02718066) | HUYABIO International, LLC. | 2016-08-18 |
| An Investigational Study of Infliximab With Prednisone or Methylprednisolone Versus Prednisone Combination Treatment in Immune Related or Severe Diarrhea in Patients Treated With Yervoy and/or Opdivo (NCT02763761) | Bristol-Myers Squibb | 2016-08-16 |
| Focal Ablative STereotactic Radiosurgery for Cancers of the Kidney (NCT02613819) | Trans Tasman Radiation Oncology Group | 2016-07-01 |
| A Study of Combinations of D-CIK Immunotherapy And Anti-PD-1 In Refractory Solid Tumors (NCT02886897) | Sun Yat-sen University | 2016-07-01 |
| Vaccine Therapy and Pembrolizumab in Treating Patients With Solid Tumors That Have Failed Prior Therapy (NCT02432963) | City of Hope Medical Center | 2016-06-14 |
| Study of Nintedanib Plus Bevacizumab in Advanced Solid Tumors (NCT02835833) | University of Alabama at Birmingham | 2016-06-09 |
| Plasma Glycosaminoglycans as Diagnostic and Prognostic Biomarkers in Surgically Treated Renal Cell Carcinoma (NCT03471897) | Chalmers University of Technology | 2016-04-28 |
| NCCN Renal Cell Registry (NCT02677337) | Duke University | 2016-03-01 |
| Whey Protein Supplement in Combination With Physical Exercise and Nutrition Program (NCT02585362) | Kantonsspital Winterthur KSW | 2016-03-01 |
| Phase I/Ib Study of Pembrolizumab With Vorinostat for Patients With Advanced Renal or Urothelial Cell Carcinoma (NCT02619253) | Nabil Adra | 2016-02-23 |
| Surgical Treatment of Pancreatic RCC Metastases (NCT03670992) | Azienda Policlinico Umberto I | 2016-01-10 |
| An Investigational Immuno-therapy Safety Trial of Nivolumab in Patients With Advanced or Metastatic Renal Cell Carcinoma (NCT02596035) | Bristol-Myers Squibb | 2016-01-08 |
| Robot-Assisted Laparoscopic Radio Frequency Ablation Assisted Enucleation of Renal Cell Carcinoma With T1a Stage (NCT02924597) | RenJi Hospital | 2016-01-01 |
| Transperitoneal vs Retroperitoneal Laparoscopic or Robotic Partial Nephrectomy (NCT02849119) | Samsung Medical Center | 2016-01-01 |
| Intraoperative Folate Targeted Fluorescence in Renal Cell Carcinoma (NCT02645409) | Chandru Sundaram | 2015-12-29 |
| Post-Marketing Surveillance Study To Observe INLYTA® Treatment Dosing Pattern, Safety And Effectiveness In Taiwan Real World Routine Practice (NCT02533258) | Pfizer | 2015-12-02 |
| Zirconium-89-girentuximab PET/CT Imaging in Renal Cell Carcinoma (NCT02883153) | Radboud University Medical Center | 2015-12-01 |
| Basket Study of Entrectinib (RXDX-101) for the Treatment of Patients With Solid Tumors Harboring NTRK 1/2/3 (Trk A/B/C), ROS1, or ALK Gene Rearrangements (Fusions) (NCT02568267) | Hoffmann-La Roche | 2015-11-19 |
| A Study of DSP-7888 Dosing Emulsion in Adult Patients With Advanced Malignancies (NCT02498665) | Sumitomo Pharma America, Inc. | 2015-11-01 |
| Study of PSMA-targeted 18F-DCFPyL PET/CT in the Evaluation of Patients With Renal Cell Carcinoma (NCT02687139) | Johns Hopkins University | 2015-10-01 |
| INC280 Combined With Bevacizumab in Patients With Glioblastoma Multiforme (NCT02386826) | SCRI Development Innovations, LLC | 2015-09-22 |
| Study of Cabiralizumab in Combination With Nivolumab in Patients With Selected Advanced Cancers (NCT02526017) | Five Prime Therapeutics, Inc. | 2015-09-08 |
| A Pilot Study of SBRT With Adjuvant Pazopanib for Renal Cell Cancer (NCT02307474) | Case Comprehensive Cancer Center | 2015-09-01 |
| Vandetanib in Combination With Metformin in People With HLRCC or SDH-Associated Kidney Cancer or Sporadic Papillary Renal Cell Carcinoma (NCT02495103) | National Cancer Institute (NCI) | 2015-08-26 |
| Prospective Patient Reported Outcomes (PRO) Registry in Patients With Advanced Renal Cell Carcinoma (NCT02537743) | iOMEDICO AG | 2015-08-19 |
| A Prospective Study on Sunitinib as First Line Therapy for Advanced/Metastatic Renal Cell Carcinoma in Asian Population (NCT02626754) | vghtpe user | 2015-08-12 |
| Cabozantinib S-malate and Nivolumab With or Without Ipilimumab in Treating Patients With Metastatic Genitourinary Tumors (NCT02496208) | National Cancer Institute (NCI) | 2015-07-22 |
| Outcome-related Factors in Patients With Metastatic Renal Cell Carcinoma Treated With Everolimus (ORCHIDEE) (NCT02338570) | Mario Negri Institute for Pharmacological Research | 2015-07-01 |
| Adaptive Staged Stereotactic Body Radiation Therapy in Treating Patients With Spinal Metastases That Cannot Be Removed by Surgery (NCT02527304) | Albert Einstein College of Medicine | 2015-06-01 |
| Neo-adjuvant SABR for IVC Tumor Thrombus in Newly Diagnosed RCC (NCT02473536) | University of Texas Southwestern Medical Center | 2015-06-01 |
| Dried Blood SPOT Analysis of Everolimus in Cancer Patients (SPOT-study) (NCT02809404) | Radboud University Medical Center | 2015-06-01 |
| Assessment of QoL and Outcomes With SBRT for RCC (NCT03108703) | Sunnybrook Health Sciences Centre | 2015-06-01 |
| A Study of Atezolizumab in Combination With Bevacizumab Versus Sunitinib in Participants With Untreated Advanced Renal Cell Carcinoma (RCC) (NCT02420821) | Hoffmann-La Roche | 2015-05-20 |
| Observational Study Evaluating The Efficacy And Effects On Quality Of Life Of Targeted Treatments Following TKIs In mRCC (NCT02315755) | Pfizer | 2015-05-11 |
| Two and Three Dimensional Contrast-enhanced Ultrasound for Screening of Renal Cell Carcinoma Recurrence Following Cryoablation (NCT02440334) | Thomas Jefferson University | 2015-04-23 |
| A Study of Anti-PD1 (Nivolumab) Therapy as Pre- and Post-operative Therapy in Metastatic Renal Cell Cancer (ADAPTeR) (NCT02446860) | Royal Marsden NHS Foundation Trust | 2015-04-01 |
| Frequency and Clinical Phenotype of BAP1 Hereditary Predisposition Syndrome (NCT04792463) | Mohamed Abdel-Rahman | 2015-03-03 |
| Simvastatin With Topotecan and Cyclophosphamide in Relapsed and/or Refractory Pediatric Solid and CNS Tumors (NCT02390843) | Emory University | 2015-02-01 |
| Study of High Dose Interleukin-2 (IL-2) and Stereotactic Body Radiation (SBRT) in Patients With Metastatic Renal Cancer (NCT02306954) | Providence Health & Services | 2014-12-01 |
| Combined Alternating Sunitinib and Bevacizumab (Avastin®) in Advanced Renal Cell Carcinoma (CASA) (NCT02919371) | King Faisal Specialist Hospital & Research Center | 2014-12-01 |
| A Phase 1, Dose-Escalation Trial of PT2385 Tablets In Patients With Advanced Clear Cell Renal Cell Carcinoma (MK-3795-001) (NCT02293980) | Peloton Therapeutics, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA) | 2014-11-25 |
| Bioequivalence & Food Effect Study in Patients With Solid Tumor or Hematologic Malignancies (NCT02223052) | Celgene | 2014-10-27 |
| Evaluation of Pathway Modulation by Raf, MEK, & Kinase Inhibitors (NCT03176485) | University of Arizona | 2014-10-17 |
| MRI in Renal Tumors (NCT02325921) | Radboud University Medical Center | 2014-10-01 |
| Comparison of Microwave Ablation-Assisted Enucleation and Conventional Laparoscopic Partial Nephrectomy in the Treatment of T1a Renal Cell Carcinoma (NCT02326558) | RenJi Hospital | 2014-10-01 |
| A Dose Finding Study To Evaluate Safety, Drug Interaction, Tumor Markers Of Axitinib In Combination With MK-3475 In Adult Patients With Previously Untreated Advanced Renal Cell Cancer (NCT02133742) | Pfizer | 2014-09-16 |
| Safety Study of SGN-CD70A in Cancer Patients (NCT02216890) | Seagen Inc. | 2014-08-01 |
| Post Marketing Surveillance for PROSENSE™ a Cryotherapy Treatment of Renal Cell Carcinoma (NCT02399124) | IceCure Medical Ltd. | 2014-07-01 |
| Investigating a Novel Modifiable Factor Affecting Renal Function After Partial Nephrectomy: Cortical Renorrhaphy (NCT02131376) | Indiana University | 2014-05-09 |
| Trial Comparing Stereotactic Body Radiation Therapy to Radiofrequency Ablation for Renal Cell Carcinoma (NCT02138578) | University of Michigan Rogel Cancer Center | 2014-05-01 |
| Molecular Determinants for Therapy Response on Renal Cell Carcinoma (NCT02208128) | Heidelberg University | 2014-05-01 |
| Quantitative Imaging Metrics From CECT in Measuring Disease Response or Progression in Patients With Kidney Cancer (NCT02370290) | University of Southern California | 2014-04-01 |
| Safety and Tolerability of Pembrolizumab (MK-3475) + Pegylated Interferon Alfa-2b and Pembrolizumab+ Ipilimumab in Participants With Advanced Melanoma or Renal Cell Carcinoma (MK-3475-029/KEYNOTE-29) (NCT02089685) | Merck Sharp & Dohme LLC | 2014-03-17 |
| A Study of Emibetuzumab in Combination With Ramucirumab (LY3009806) in Participants With Advanced Cancer (NCT02082210) | Eli Lilly and Company | 2014-03-07 |
| Characterization of Circulating Tumor Cells Captured by c-MET (CTC-MET) (NCT02080650) | Duke University | 2014-03-01 |
| Safety Study of Cord Blood-derived Cytokine-induced Killer Cells in Patients With Solid Tumor After Radical Resection (NCT01914263) | Alliancells-PuRui Biocience Co., Ltd. | 2014-03-01 |
| Study of the Glutaminase Inhibitor CB-839 in Solid Tumors (NCT02071862) | Calithera Biosciences, Inc | 2014-02-01 |
| Metabolomic Profiling in Renal Cell Carcinoma (NCT02001493) | Cambridge University Hospitals NHS Foundation Trust | 2014-01-01 |
| A Phase 1 Study to Evaluate MEDI4736 in Combination With Tremelimumab (NCT01975831) | Ludwig Institute for Cancer Research | 2013-12-19 |
| Phase II Study of Anlotinib in Patients With Advanced Renal Cell Carcinoma That Have Failed Or Are Intolerant To TKIs Therapy (NCT02072044) | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | 2013-12-01 |
| A Phase 1 Study of Pegilodecakin (LY3500518) in Participants With Advanced Solid Tumors (NCT02009449) | Eli Lilly and Company | 2013-11-15 |
| Tumor Collection From Routine Nephrectomy for Subjects With Advanced Stage RCC (NCT02143492) | Argos Therapeutics | 2013-08-01 |
| The Intrathecal Morphine for Nephrectomy (NCT01997788) | Seoul National University Hospital | 2013-08-01 |
| DC Vaccine Combined With CIK Cells in Patients With Renal Cell Carcinoma (NCT01924156) | Affiliated Hospital to Academy of Military Medical Sciences | 2013-07-01 |
| A Phase II Study of Cyberknife Radiosurgery for Renal Cell Carcinoma (NCT01890590) | Beth Israel Deaconess Medical Center | 2013-07-01 |
| A Post Marketing Surveillance As Required By Philippine Food And Drug Administration (NCT01781442) | Pfizer | 2013-06-01 |
| A Study of Cabozantinib (XL184) vs Everolimus in Subjects With Metastatic Renal Cell Carcinoma (NCT01865747) | Exelixis | 2013-06-01 |
| Tivozanib + Gemcitabine in Metastatic RCC (NCT01834183) | Dana-Farber Cancer Institute | 2013-06-01 |
| Study of Segmental Renal Artery Clamping During Laparoscopic Partial Nephrectomy (NCT01892059) | The First Affiliated Hospital with Nanjing Medical University | 2013-05-01 |
| Intraoperative Imagery of Renal Nodules With Folate-fluorescein Conjugate(EC17) (NCT01778933) | University of Pennsylvania | 2013-05-01 |
| Zero Ischemia Laparoscopic Radio Frequency Ablation Assisted Enucleation of Renal Cell Carcinoma With T1a Stage (NCT01838720) | RenJi Hospital | 2013-04-01 |
| A Multicenter Phase I Study of MRX34, MicroRNA miR-RX34 Liposomal Injection (NCT01829971) | Mirna Therapeutics, Inc. | 2013-04-01 |
| Randomized Phase 2 Trial of Axitinib and TRC105 Versus Axitinib Alone in Patients Renal Cell Carcinoma (NCT01806064) | Tracon Pharmaceuticals Inc. | 2013-03-08 |
| A Phase 2 Study of ASONEP™ to Treat Unresectable and Refractory Renal Cell Carcinoma (NCT01762033) | Lpath, Inc. | 2013-02-01 |
| A Phase II Study of Axitinib in Metastatic Non-clear Cell Renal Cell Carcinoma Patients Previously Treated With Temsirolimus (NCT01798446) | Seoul National University Hospital | 2013-02-01 |
| Contrast-Enhanced Ultrasound in Predicting Treatment Response in Patients With Kidney Cancer Undergoing Cryosurgery (NCT02671552) | Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University | 2013-01-24 |
| Evaluation of the Safety of Reoperation for Ipsilateral Recurrent Tumors After Nephron-sparing Partial Nephrectomy (NCT06317207) | The First Affiliated Hospital of Anhui Medical University | 2013-01-01 |
| Effect of Ketorolac and Remote Ischemic Preconditioning on Renal Ischemia-reperfusion Injury in Patients Undergoing Partial Nephrectomy (NCT01836406) | Yonsei University | 2012-12-01 |
| Duration of Treatment With Tyrosine Kinase Inhibitors in the Treatment of Metastatic Renal Cell Carcinoma (NCT01585974) | Bayer | 2012-10-01 |
| Remote Ischemia Pre-Conditioning in Patients Undergoing Partial Nephrectomy (NCT01771003) | University Health Network, Toronto | 2012-10-01 |
| A Study of CD45RA+ Depleted Haploidentical Stem Cell Transplantation in Children With Relapsed or Refractory Solid Tumors and Lymphomas (NCT01625351) | St. Jude Children's Research Hospital | 2012-08-20 |
| Imaging Correlates of Renal Cell Carcinoma Biological Features (NCT01665703) | UNC Lineberger Comprehensive Cancer Center | 2012-08-01 |